Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > screenshot question
View:
Post by DJDawg on Jul 27, 2021 3:51pm

screenshot question

Regarding the recent AGM screenshot from recently.....

- the most recent documents talk about the 7 optimized Primary and then the 11 that go a do-over with an optimized "Maintenance" treatment. I'm assuming that for those of the 11 that were grossly underdosed before, this optimized treatment would be kind of like a first real treatment.
- if so, how do we see them in the screenshot? One would assume it would show as PR patients jumping into the CR group count. Or NR patients jumpting into the CR or PR groupings. Which we are not seeing. I personally wonder if they 11 optimized Maintenance patients are not represented on the table at all...yet.

Incidentally, I can see why they picked 6 m for the second treatment in all comers. The CR and PR group numbers holds from 90 to 180 days and then starts losing patients. So that logic is good to see.

I've seen some pharma results where they show every patient's journey individually so you can see where they are. Wish they did that here.
Comment by CancerSlayer on Jul 27, 2021 4:39pm
Hi DJDawg...Per the Sept. 24 release: Study II has enrolled and treated 12 patients to date. Out of the 7 patients that are eligible to receive the second treatment, 5 have been treated and 2 are pending. 2 out of the last 5 patients treated for the second time have been treated with the optimized Study II treatment, which will also be the case for the 2 patients that are pending their second ...more  
Comment by enriquesuave on Jul 27, 2021 5:05pm
I'm pretty sure the mention of 11 patients having received an optimised treatment is an error.  It may be more like 5-6 of which we only see 2or 3 on AGM slide.  IMO 
Comment by enriquesuave on Jul 27, 2021 5:54pm
should have read a 2nd optimized treatment.
Comment by DJDawg on Jul 27, 2021 5:56pm
Thanks. I'd like to say that I'm not confused anymore but the way they represent data is so frustrating. In a way I'm glad that they have done a reboot and are showing the optimized from day 1 has a new pie chart of its own. BTW - it is interesting how the most recent newsletter has the optimized pie chart and adjacent table with different information. The pie chart says 1 patient is ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250